Pembrolizumab Plus Chemotherapy Continues to Display Survival Advantage Over Chemotherapy in NSCLC
Patients with metastatic squamous non–small cell lung cancer experienced a clinically meaningful survival benefit when treated with pembrolizumab in combination with chemotherapy.